Elizabeth Zhang
About Elizabeth Zhang
Elizabeth Zhang is a Corporate Counsel at Nektar Therapeutics, with a strong educational background in Neuroscience and Law from prestigious institutions. She has previously held associate positions at several prominent law firms, including Cravath, Swaine & Moore LLP and Gibson, Dunn & Crutcher LLP.
Work at Nektar Therapeutics
Elizabeth Zhang has been serving as Corporate Counsel at Nektar Therapeutics since 2021. In this role, she provides legal guidance and support to the organization, focusing on compliance and regulatory matters. Nektar Therapeutics is a biopharmaceutical company based in San Francisco, specializing in innovative therapies for patients with serious diseases.
Education and Expertise
Elizabeth Zhang holds a Master of Science (M.Sc.) in Neuroscience from the University of Oxford, which she completed from 2010 to 2011. She also earned a Bachelor of Arts (B.A.) in Neurobiology from Harvard University, studying from 2006 to 2010. Additionally, she obtained her Juris Doctor from Harvard Law School, where she studied from 2011 to 2014. Her educational background provides her with a strong foundation in both legal and scientific disciplines.
Background in Law Firms
Prior to her current position, Elizabeth Zhang worked at several prestigious law firms. She was an Associate at Cravath, Swaine & Moore LLP from 2014 to 2018, and again as a Summer Associate in 2013. She also served as an Associate at Gibson, Dunn & Crutcher LLP from 2018 to 2019 and from 2019 to 2021 in New York and San Francisco, respectively. Additionally, she was a Summer Associate at Orrick, Herrington & Sutcliffe LLP in 2012.
Professional Experience Timeline
Elizabeth Zhang's professional journey includes various roles across notable law firms and her current position at Nektar Therapeutics. She began her legal career as a Summer Associate at Orrick, Herrington & Sutcliffe LLP in 2012, followed by a Summer Associate role at Cravath, Swaine & Moore LLP in 2013. She then became an Associate at Cravath from 2014 to 2018, transitioned to Gibson, Dunn & Crutcher LLP from 2018 to 2019, and continued there until 2021. She has been with Nektar Therapeutics since 2021.